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Abstract
Dysferlinopathies are caused by mutations in theDYSF gene and patients may present with proximal or distal myopathy. Dysferlin is responsible
for membrane resealing, and mutations may result in a defect in membrane repair following mechanical or chemical stress, causing an influx of
Ca2+. Since mitochondria are involved in Ca2+ buffering, we hypothesised that mitochondrial defects may be present in skeletal muscle biopsies
from patients with mutations in this gene. The aim was to characterise mitochondrial defects in muscle from patients with dysferlinopathies. Here,
we analysed skeletal muscle biopsies for eight patients by quadruple immunofluorescent assay to assess oxidative phosphorylation protein
abundance. Long-range PCR in single muscle fibres was used to look for presence of clonally expanded large-scale mitochondrial DNA
rearrangements in patients’ skeletal muscle (n = 3). Immunofluorescence demonstrated that the percentage of complex I- and complex IV-deficient
fibres was higher in patients with DYSF mutations than in age-matched controls. No clonally expanded mtDNA deletions were detected using
long-range PCR in any of the analysed muscle fibres.We conclude that complex I and complex IV deficiency is higher in patients than age matched
controls but patients do not have rearrangements of the mtDNA.We hypothesise that respiratory chain deficiency may be the results of an increased
cytosolic Ca2+ concentration (due to a membrane resealing defect) causing mitochondrial aberrations.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
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1. Introduction
Dysferlin mutations cause a number of different phenotypes
including limb girdle muscle dystrophy type 2B (LGMD2B),
Miyoshi distal myopathy (MM) [1,2] and distal myopathy with
Anterior Tibialis onset (DMAT) [3]. Links between mutation
type, location and phenotype are not straight forward [4,5].
These conditions demonstrate a multitude of dystrophic
features including necrotic fibres, fibre splitting, variation in
fibre size, and sometimes inflammatory infiltrates [6]. Dysferlin
is responsible for plasma membrane repair, vesicle fusion
and membrane trafficking. The ferlin protein group to which
dysferlin belongs all have Ca2+ sensitive C2 domains [7];
dysferlin itself has seven C2 domains with variable affinities for
Ca2+ [8]. It has previously been demonstrated that an influx of
Ca2+ through the site of membrane injury triggers dysferlin-
mediated membrane repair [9]. Patients with mutations in
the dysferlin gene often have impaired membrane resealing
following mechanical or chemical stress, causing an influx of
Ca2+. This is particularly relevant in muscle where mechanical
stress due to muscle contraction is quite common and Ca2+
regulation is highly important.
To date, two reports have been published documenting
mitochondrial abnormalities in patients with dysferlin
mutations. The first report demonstrated accumulation of
subsarcolemmal mitochondria in some patients’ muscle fibres
including one patient with ragged red fibres and paracrystalline
mitochondrial inclusions [10]. More recently up to 10% of
muscle fibres were reported to be cytochrome c oxidase
(COX or complex IV) deficient, and some of these fibres
have increased mtDNA copy number [11]. In the same
study, a reduced complex IV and complex III levels were
observed in some patients, while others showed a significant
downregulation of complex I and complex IV activities and
only a mild reduction of complex III.
Here, we employ a recently developed immunofluorescent
technique [12] to measure levels of complex I and complex IV
* Corresponding author. Wellcome Trust Centre for Mitochondrial Research,
Institute of Neuroscience, Newcastle University, Newcastle upon Tyne NE2
4HH, UK. Fax: 0044-1912228553.
E-mail address: doug.turnbull@ncl.ac.uk (D.M. Turnbull).
http://dx.doi.org/10.1016/j.nmd.2016.08.008
0960-8966/© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/
4.0/).
Available online at www.sciencedirect.com
Neuromuscular Disorders 26 (2016) 782–788
www.elsevier.com/locate/nmd
ScienceDirect
normalised to porin as a mitochondrial mass marker. This
technique, unlike COX/SDH histochemistry allows us to
accurately and objectively quantify the extent of mitochondrial
respiratory chain deficiency. We also hypothesise that
increased mitochondrial fission due to increased cytosolic Ca2+
may reduce mtDNA stability. Therefore, we also employ long-
range PCR to look for the presence of large-scale mtDNA
rearrangements. Accurate and objective quantification of
complex I and complex IV levels and mtDNA deletion analysis
provide a novel addition to previous investigations in patients
with dysferlin mutations.
2. Patients and methods
2.1. Patient cohort
Muscle biopsies were taken for diagnostic purposes from
patients (n = 8), with a suspected neuromuscular condition; all
patients consented to the use of the sample for research.
Diagnostic immunohistochemistry and western blotting
showed an absence of dysferlin. Sequencing of the DYSF
gene identified pathogenic mutations (Table 1), confirming a
diagnosis of dysferlinopathy. Eight patients included in the
study (numbered 1–8 based on age); six were diagnosed with
Limb Girdle Muscular Dystrophy type 2B (LGMD2B) and two
with Miyoshi myopathy (MM). Patients were numbered 1 to 8
based on age at biopsy. A muscle biopsy from a previously-
reported patient with an mtDNA maintenance disorder and
multiple deletions due to recessive RRM2B variants [13]
was used as a positive control, as well as 3 healthy control
biopsies from subjects aged 18, 35 and 52 years at the time of
biopsy.
2.2. Histochemistry
Cryosections (10 μm) were obtained from transversely-
orientated muscle blocks and subjected to COX/SDH
(cytochrome c oxidase/succinate dehydrogenase) histochemistry.
Three serial sections were used to detect: COX activity, SDH
activity and combinedCOX/SDHactivity, as describedpreviously
[14]. Numbers of COX-deficient fibres were counted in a defined
area for each section using the meander scan function in Stereo
Investigator and a Stereology microscope (Olympus BX51).
Serial sections were stained with haematoxylin and eosin
(H&E) to examine muscle morphology. Slides were assessed
independently by two investigators.
2.3. Quadruple immunofluorescence
A recently developed immunofluorescent assay was used
to assess levels of complex I and complex IV relative to
mitochondrial mass [12]. Images were stitched using ZEN
(blue edition) before analysis in IMARIS (v.8) software, and
statistical analysis was completed as described previously [12].
2.4. Laser microdissection and cell lysis
Three serial cryosections were cut. The first and last tissue
sections underwent sequential COX/SDH histochemistry and
were used to assess the degree of COX deficiency. The second
tissue section underwent SDH histochemistry only and was
used for mtDNA analysis. Single muscle fibres were laser
microdissected from the second tissue section using a PALM
system (Zeiss). Fibres from the second tissue section were
captured into 15 μl single cell lysis buffer (0.5% SDS, 10 mM
EDTA, 5% proteinase K).
2.5. Long-range PCR
Two rounds of PCR were employed to screen isolated
muscle fibres for large-scale mtDNA rearrangements using
PrimeSTAR GXL (TaKaRa, Clonetech). The reaction was
prepared as follows: 1 μl cell lysate, 1× PrimeSTAR GXL
reaction buffer, 0.2 μM dNTPs, 0.2 μM forward and reverse
primers and 0.625 unit polymerase, in a total volume of 50 μl.
The first round of PCR amplified a 16,179 bp region using
primers 2180F (nucleotides m.2180–2209) and 1789R
(nucleotides m.1760–1789) and the second round reaction
amplified a 16,029 bp region using primers 2330F (nucleotides
m.2330–2359) and 1789R (nucleotides m.1760–1789)
(NC_012920.1). Cycling conditions were: 35 cycles of 10
seconds at 98 °C and 11 minutes at 68 °C. PCR products were
separated through a 0.7% agarose gel with a 1 Kb ladder used
to size amplicons.
Table 1
Dysferlinopathy patient information.
Patient
number
Gender Age at onset
(if known)
Age at
biopsy
Mutation CK Phenotype
DYSF 1 F 10 (distal) 15.7 c.855+1delG; c.3031G>C, p.(Gly1011Arg) 3012 MM
DYSF 2 F 26 20.5 c.2434dup p.(His812Profs*53); c.1745G>T p.(Arg582Leu) 7586 LGMD2B
DYSF 3 F 26 21.9 Hom. c.2163-1G>T 13,000 LGMD2B
DYSF 4 M Birth 24.7 Hom. c.1480+18T>C; c.4999G>A, p.(Glu1667Lys) 400–700 LGMD2B
DYSF 5 M 9 28.9 exon 5–10 deletion; c.757C>T, p.(Arg253Trp) 5000 LGMD2B
DYSF 6 M Late teens (distal) 30.4 Hom. c.3059dupC, p.(Glu1021Glyfs*10) 20,000 MM
DYSF 7 F N/K 47.1 c. 5509G>A, p.(Asp1837Asn); c.6124C>T, p.(Arg2042Cys) 5110 LGMD2B
DYSF 8 M 13 52.5 c.3512_3513delCT, p.(Ser1171Phefs*3); c.5908C>T, p.(Pro19070Ser) 6000 LGMD2B
Notes: Patients are organised in age order and all mutation nomenclature uses the primary transcript (NM_003494.3). All biopsies were taken from the quadriceps
via needle biopsy.
N/K; Not known; M: Male; F: Female; Hom.: homozygous; LGMD2B: Limb girdle muscular dystrophy type 2B; MM: Miyoshi Myopathy.
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3. Results
3.1. COX/SDH histochemistry and haematoxylin and eosin
H&E staining demonstrated a large variability in fibre size.
There were also many necrotic fibres, internal nuclei and in
some cases inflammatory infiltrates mostly associated with
(but not limited to) necrotic fibres (Fig. 1, left column).
COX/SDH histochemistry demonstrated a small number (typically
less than 1%) of COX deficient fibres (Fig. 1, right column).
However, many biopsies had a large number of fibres that
appeared to have intermediate levels of COX deficiency, which
was difficult to assess visually (Fig. 1, DYSF 3). Stereoinvestigator
and a stereology microscope were used to count the number of
COX positive, intermediate positive, intermediate negative and
negative fibres in a defined region (Table 2). Due to very few
truly COX-deficient fibres and many more COX-intermediate
muscle fibres, deficiency level was likely to be under- or
overestimated. Furthermore, counts between 2 investigators
varied due to a large number of fibres intermediate for COX
activity, which demonstrated the necessity of applying the
objective quantitative immunofluorescence to more accurately
assess COX levels.
3.2. Immunofluorescent analysis of respiratory chain
complexes
Quadruple immunofluorescence allowed objective
quantification of complex I and complex IV protein abundance.
Results are summarised in Table 3. Immunofluorescent images
for DYSF 4, 6 and 8 (Fig. 2) demonstrate complex I- and
complex IV-deficient fibres. In 18 and 34 year old control
biopsies, complex I deficiency is absent, but present in
Fig. 1. Histochemical analysis of serial muscle section.
Notes: Serial muscle sections from patients 3, 6 and 8, for H&E, COX, SDH and sequential COX/SDH histochemistry. H&E demonstrates large variation in fibre
size, with occasional internal nuclei and inflammation. Only DYSF 6 shows a clear cut COX negative fibre but all three biopsies show evidence of intermediate fibres.
Table 2
COX deficiency for dysferlin patients (n = 8) as assessed by sequential COX/
SDH histochemistry.
Investigator Patient Total
fibres
% COX
positive
%
Intermediate
positive
%
Intermediate
negative
% COX
negative
1 DYSF 1 1491 98.2% 1.8% 0.0% 0.0%
DYSF 2 577 75.4% 18.4% 6.1% 0.1%
DYSF 3 963 65.5% 21.9% 11.9% 0.6%
DYSF 4 1774 97.7% 5.0% 0.1% 0.0%
DYSF 5 397 86.9% 12.8% 0.3% 0.0%
DYSF 6 563 80.8% 17.9% 0.9% 0.4%
DYSF 7 132 69.7% 30.3% 0.0% 0.0%
DYSF 8 453 92.5% 4.9% 2.0% 0.7%
2 DYSF 1 1357 83.6% 16.3% 0.07% 0.0%
DYSF 2 382 71.7% 26.9% 1.5% 0.0%
DYSF 3 328 65.9% 30.4% 3.7% 0.0%
DYSF 4 1131 97.1% 2.6% 0.2% 0.1%
DYSF 5 395 77.7% 22.0% 0.3% 0.0%
DYSF 6 726 70.4% 27.1% 1.9% 0.6%
DYSF 7 135 58.5% 31.1% 10.4% 0.0%
DYSF 8 463 78.2% 20.3% 1.2% 0.4%
Notes: Fibres were classified as COX positive, COX intermediate positive,
COX intermediate negative or negative in order to make it comparable with
immunofluorescent assessment.
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approximately 0.5% fibres in the 52 year old control. In
contrast, complex I deficiency ranged from 0% in two patients
to 29.4% in patient 3. These levels were much higher than we
expected in age matched healthy individuals but lower than
those found in the patient with recessive RRM2B variants
(36.2%).
The 18 and 34 year old control biopsies demonstrated
no complex IV deficient fibres and the 52 year old had
approximately 0.5%. In contrast to this, 0.1–11.1% of patients’
muscle fibres had evidence of complex IV deficiency. A higher
proportion of muscle fibres are complex IV deficient than in the
age-matched controls and previous reports of age-related
complex IV deficiency [15]. However, in comparison to the
patient with RRM2B variants whose biopsy harboured 23.2%
complex IV deficient fibres, the degree of deficiency in the
dysferlin patient is low.
Table 3
Immunofluorescent analysis of respiratory chain protein expression.
Patient Age/
years
Complex I
negative/%
Complex I
deficient/%
Complex IV
negative/%
Complex IV
deficient/%
DYSF 1 15.7 2.03 12.26 0.58 6.62
18 years (-ve C) 18 0 0 0 0
DYSF 2 20.5 0 0.00 0 0.05
DYSF 3 21.9 26.1 29.42 0 11.05
DYSF 4 24.7 0.09 0.85 1.13 4.7
DYSF 5 28.9 0.15 0.48 0.12 0.33
DYSF 6 30.4 1.78 7.43 1.24 3.05
34 years (-ve C) 34 0.18 0.6 0.18 0.3
DYSF 7 47.1 0 0.00 0 5.05
52 years (-ve C) 52 0 0 0 0
DYSF 8 52.5 1.96 10.79 0.44 1.31
Notes: Summary of percentage of fibres classified as complex-I and
complex-IV negative or deficient (negative and intermediate categories).
Controls and patients are organised in age for easy comparison.
Fig. 2. Quadruple immunofluorescent analysis of mitochondrial respiratory chain deficiency.
Notes: Representative images of NDUFB8 (complex I) (purple), porin (red) and COX-I (complex IV) (red). Immunofluorescent staining in a 52 year old negative
control and dysferlin patients 4, 6 and 8. Fibres deficient for complex I and complex IV (x in DYSF4 and DYSF8), complex IV only (# in DYSF8) and complex I
only (arrow head in DYSF8) can be seen. Scale bar 100 μm.
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The respiratory expression profiles in Fig. 3 demonstrate
three clear patterns of mitochondrial respiratory chain
protein levels. Dysferlin patients 1, 3 and 6 (Fig. 3a, c and f
respectively) had large number of fibres which were complex
I-deficient. Dysferlin patient 4 (Fig. 3d) had a larger number
of complex IV-deficient fibres than complex I-deficient
fibres. Patients, 2, 5, 7 and 8 (Fig. 3b, e, g and h respectively)
demonstrated very little deficiency affecting either respiratory
chain complex. All dysferlinopathy patients had lower levels of
respiratory chain deficiency than the RRM2B patient (Fig. 3i)
Fig. 3. Mitochondrial respiratory chain expression profiles displaying complex I, complex IV and porin levels in patients with DYSF mutations and an RRM2B
mutation as a mitochondrial disease control. (a) DYSF 1, (b) DYSF 2, (c) DYSF 3, (d) DYSF 4, (e) DYSF 5, (f) DYSF 6, (g) DYSF 7, (h) DYSF 8 and (i) RRM2B
patient positive control.
Notes: Each point gives the complex I and complex IV z-scores for a single fibre and is colour coded to indicate the porin category of the fibre (very low, dark blue;
low, light blue; normal, beige; high, orange; or very high red). Bars next to the X andY-axes indicate category of complex I or complex IV levels (dark blue, negative;
light blue, intermediate negative; light beige, intermediate positive and beige, normal).
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but at 43 years of age, this disease control is older than the
majority of dysferlin patients (many of whom are below the age
of 35 years).
3.3. Mitochondrial DNA genetic analysis
Patients 4, 6 and 8 were selected for genetic analysis, as
these demonstrated the most COX-deficient fibres in sections
subjected to COX/SDH histochemistry. Long-range PCR
indicated a lack of deletions in all fibres for which a product
was successfully amplified for each patient (Fig. 4a), while the
patient harbouring compound RRM2B variants demonstrated
multiple mtDNA deletions (Fig. 4b). In each of the dysferlin
patients and an RRM2B patient, a small number of fibres failed
to amplify.
4. Discussion
This study has demonstrated that the levels of complex
IV (COX) and complex I deficiency are higher in some
dysferlinopathy patients than in age-matched controls. The
majority of deficient fibres were categorised as intermediate
positive or intermediate negative rather than completely
negative. Furthermore, the percentage of complex I-deficient
fibres was higher than the percentage of complex IV deficient
fibres in many of these patients.
Long-range PCR analysis of mtDNA from three patients,
with high percentage of complex I and complex IV deficient
fibres, demonstrated only full-length mtDNA amplicons.
Despite an absence of large-scale mtDNA deletions, it is
possible that the respiratory chain dysfunction may be due to
deletions or duplications smaller than the resolution of the
technique, or indeed mtDNA point mutations. As there is a
greater percentage of complex I and complex IV deficiency in
patients compared to controls, we hypothesise that mutations in
the dysferlin protein which cause a defect in membrane
resealing and alter the ability of dysferlin to maintain Ca2+
homeostasis may also have an impact on the mitochondria. If
so, mitochondrial respiratory chain dysfunction could be
secondary to the increased cytosolic calcium concentration
which may affect mitochondrial topology.
Dysferlin, which has ferlin Ca2+ domains with variable
affinities for Ca2+ helps to regulate cytosolic Ca2+ [10]. In the
absence of functional dysferlin, cytosolic Ca2+ levels become
abnormally high. Regulation of cytosolic Ca2+ levels is also a
role of the mitochondria; as such, a shift in Ca2+ will affect
their function. Ca2+ influx into the cytoplasm increases in
mitochondrial fission and leads to fragmentation of the
mitochondrial network [16]. Mitochondrial fusion is necessary
for mtDNA stability and tolerance of mtDNA mutations, as it
allows equilibration of the mtDNA maintenance machinery
throughout the network and dilutes mutated mitochondrial
DNA reducing the impact on mitochondrial function [17].
As such, mutations in the dysferlin gene that increase Ca2+
influx and impair muscle Ca2+ homeostatic ability of the
muscle cause an increase in cytosolic Ca2+ concentration,
fragmentation of the mitochondrial network and therefore allow
mitochondrial dysfunction to accumulate and impact on tissue
functionality.
Here, we demonstrate that complex I and complex IV
deficiency is higher in patients with dysferlin mutations than in
age-matched controls. We hypothesise that this may be due to
interruption of calcium homeostasis because of the mutation in
dysferlin and defect in membrane resealing. Further testing will
be required to confirm this but may offer a potential therapeutic
target.
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